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The persistence of immunity to malaria induced in mice by a heterologous DNA priming and poxvirus
boosting regimen was characterized. Mice were immunized by priming with DNA vaccine plasmids encoding
the Plasmodium yoelii circumsporozoite protein (PyCSP) and murine granulocyte-macrophage colony-stimu-
lating factor and boosting with recombinant vaccinia encoding PyCSP. BALB/c mice immunized with either
high-dose (100 g of p PyCSP plus 30 g of pGM-CSF) or low-dose (1 g of p PyCSP plus 1 g of pGM-CSF
DNA) priming were protected against challenge with 50 P. yoelii sporozoites. Protection 2 weeks after immu-
nization was 70 to 100%, persisted at this level for at least 20 weeks, and declined to 30 to 40% by 28 weeks.
Eight of eight mice protected at 20 weeks were still protected when rechallenged at 40 weeks. The antigen
(Ag)-specific effector CD8-T-cell population present 2 weeks after boosting had ex vivo Ag-specific cytolytic
activity, expressed both gamma interferon (IFN-) and tumor necrosis factor alpha, and constituted 12 to 20%
of splenic CD8 T cells. In contrast, the memory CD8-Ag-specific-cell population at 28 weeks lacked cytolytic
activity and constituted only 6% of splenic CD8 T cells, but at the single-cell level it produced significantly
higher levels of IFN- than the effectors. High levels of Ag- or parasite-specific antibodies present 2 weeks after
boosting had declined three- to sevenfold by 28 weeks. Low-dose priming was similarly immunogenic and as
protective as high-dose priming against a 50-, but not a 250-, sporozoite challenge. These results demonstrate
that a heterologous priming and boosting vaccination can provide lasting protection against malaria in this
model system.
Immunity to malaria is often short lived. Some aspects of the
clinical immunity which develops following life-long exposure
to malaria are lost upon leaving an area where malaria is
endemic, the sterile protection induced by immunization with
radiation-attenuated sporozoites has not been shown to last
more than 9 months, and the protection afforded by a recent
candidate malaria vaccine, RTS,S (17), is short lived (16). It is
important therefore to develop model malaria vaccines that
provide long-term protection and to understand better the
immune mechanisms involved in long-term protection against
malaria.
Immunization of BALB/c mice with irradiated Plasmodium
yoelii sporozoites confers sterile protection against high-dose
challenge with infectious P. yoelii sporozoites (4, 9, 11, 20).
This protection is dependent on CD8 T cells and gamma
interferon (IFN-) (4, 10, 20). Immunization with DNA plas-
mids encoding the P. yoelii circumsporozoite protein (PyCSP)
partially protects BALB/c mice against challenge with 50 to
100 P. yoelii sporozoites (6, 12, 13, 14, 19). Like the protection
induced by immunization with irradiated sporozoites, the
DNA-vaccine-induced protection is dependent on CD8 T
cells and IFN- (5, 12). This modest protective efficacy can be
improved by adding a plasmid encoding murine granulocyte-
macrophage colony-stimulating factor (GM-CSF) to the
PyCSP plasmid (19) or by boosting with a recombinant vaccinia
encoding PyCSP (13). Recently, Sedegah et al. demonstrated
that combining these two strategies by priming with the com-
bination of DNA plasmids encoding PyCSP and murine GM-
CSF and boosting with recombinant PyCSP poxvirus induced a
substantial increase in protection, and in antibody and T-cell
responses, compared with immunizing with DNA alone (14).
In addition, we found protection could be induced even if the
priming dose of DNA was reduced 100-fold. In these studies,
protection correlated most closely with the results of ex vivo
cytotoxic T-lymphocyte (CTL) and IFN- enzyme-linked im-
munospot (ELISPOT) assays, consistent with CD8-T-cell-
and IFN--dependent protection.
Here we further characterize the immunity induced by the
DNA–GM-CSF viral boost regimen. We studied the persis-
tence of the protection, its robustness in the face of challenge
with increased numbers of infectious sporozoites, and the
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change in antibody and T-cell responses and the phenotype of
responding T cells over time.
MATERIALS AND METHODS
Mice. Four- to 6-week-old female BALB/cByJ (H-2d) mice were purchased
from Jackson Laboratories (Bar Harbor, Maine) and used in all experiments.
The experiments reported herein were conducted according to the principles set
forth in Guide for the Care and Use of Laboratory Animals (9a).
Parasites. P. yoelii (17XNL nonlethal strain, clone 1.1) parasites were main-
tained by alternating passage of the parasites in Anopheles stephensi mosquitoes
and CD-1 mice. Sporozoites for challenge studies were obtained by hand dissec-
tion of infected mosquito glands in M199 medium containing 5% normal mouse
serum 14 days after the mosquitoes had taken an infectious blood meal. Isolated
sporozoites were diluted to a final concentration of 250 to 1,250 infectious
sporozoites per ml.
Parasite challenge. Parasite challenge was accomplished by injecting 50 or 250
sporozoites into the tail vein, in a volume of 200 l, at 2, 4, 8, 12, 16, 20, 28, or
40 weeks postimmunization. Giemsa-stained blood films were prepared on days
5 to 14 postchallenge and examined microscopically for the presence of parasites,
with up to 50 oil-immersion fields examined. Protection was defined as the
complete absence of blood-stage parasitemia at all time points.
Immunogens. The plasmid DNA constructs encoding PyCSP in the VR1020
backbone (VR2516), designated p PyCSP herein, and the murine GM-CSF
plasmid (VR1701), designated pGM-CSF herein, have been described previously
(13, 19). Plasmid DNA was purified by using cesium chloride-ethidium bromide
density gradient centrifugation. Plasmids were stored at 20°C and diluted in
phosphate-buffered saline (PBS) (pH 7.2) to the appropriate concentration for
injection. The recombinant vaccinia virus construct encoding PyCSP, designated
rv PyCSP herein, and control virus have been described previously (13).
Immunizations. For high-dose (DG-V) immunization, 100 g of p PyCSP was
mixed with 30 g of pGM-CSF; for low-dose (dg-V) immunization, 1 g of p
PyCSP was mixed with 1 g of pGM-CSF. Negative-control mice were injected
with unmodified plasmid DNA (VR1020). In all cases, mice received the total
dose in two 50-l intramuscular injections with a 0.3-ml insulin syringe with a
29.5-gauge needle; one injection in each tibialis anterior muscle. Mice received
a boost intraperitoneally of 2  107 rv PyCSP or of control virus (vP993)
containing no foreign gene delivered in a total volume of 0.2 ml of PBS with a
1-ml insulin syringe with a 26.5-gauge needle 3 weeks after priming with DNA.
Antibody assays. P. yoelii sporozoite-specific antibodies in prechallenge sera
were assayed by immunofluorescent staining of air-dried P. yoelii sporozoites as
described previously (3, 13). PyCSP-specific antibodies were assayed by standard
enzyme-linked immunosorbent assay with a full-length recombinant PyCSP pro-
duced in yeast or linear synthetic peptide containing four copies of the major
PyCSP repeat, (QGPGAP), as solid-phase antigens by using previously described
methods(3).
CTL assays. Standard restimulated CTL assays were carried out as described
previously (14) with a 16-mer peptide derived from the PyCSP [PyCSP(280-296),
SYVPSAEQILEFVKQI] for restimulation and a 9-mer peptide [PyCSP(280-
288), SYVPSAEQI] for target sensitization. The percent lysis was determined
with the following formula: (experimental release  medium control release)/
(maximum release  medium control release)  100. The percent specific lysis
was calculated by subtracting the percent lysis of the control targets from the
percent lysis of the specific peptide. Alternatively, freshly isolated immune spleen
cells were used as effectors in 51Cr release assays without the standard 6- to 7-day
in vitro restimulation period. In brief, for effectors, various ratios (effector-to-
target cell ratio  300:1, 150:1, 75:1, and 37.5:1) of freshly isolated spleen cells
suspended in complete medium containing 2% rat T-cell stim (Collaborative
Biomedical Products Inc., Bedford, Mass.) were added to 96-well round bottom
plates in a volume of 100 l per well in triplicate. For targets, P815 (H-2d) cells
(American Type Culture Collection, Rockville, Md.) were labeled overnight with
0.1 mCi of 51Cr (Dupont-New England Nuclear Inc., Boston, Mass.). Immedi-
ately before the assay, 51Cr-labeled target cells were washed three times with
complete medium and resuspended at a concentration of 5  104 cells per ml.
For experimental targets, PyCSP(280-288) (SYVPSAEQI) was added at a con-
centration of 0.025 M. The control targets did not receive any peptide. Target
cells were aliquoted at a concentration of 5,000 cells/100 l/well to wells con-
taining effector cells or to control wells. Supernatants were harvested after a 12-h
incubation period by using the Skatron harvesting system, and percent lysis was
determined as described above.
Intracellular cytokine staining. Spleen cells (5  105) from immunized or
control mice were aliquoted into 96-well U bottom plates containing PyCSP(280-
288) peptide-pulsed P815 cells (1  105) and brefeldin A (2 g/ml), in a total
volume of 200 l of complete medium/well. Cells were cultured for 16 h at 37°C
in a 5% CO2 humidified incubator. Following culture, cells were washed with
cold PBS and stained with cell surface antibodies to CD8, CD62L, CD44,
CD45RB, and CD69 (Pharmingen, San Diego, Calif.) for 20 min on ice. Cells
were washed twice and permeabilized in 100 l of Cytofix/Cytoperm buffer
(Pharmingen) according to the manufacturer’s directions. Cells were then
stained intracellularly for IFN- and tumor necrosis factor alpha (TNF-) by
using phycoerythrin-conjugated monoclonal antibodies to IFN- or TNF-
(Pharmingen) at a concentration of 0.4 g of antibody/106 cells. Samples were
acquired by using a four-color FACSCALIBUR (Becton Dickinson, San Jose,
Calif.). For each sample, 80,000 to 200,000 events were acquired. Cytokine
expression on gated CD8 T cells was analyzed with Cellquest software (Becton
Dickinson). All assays were performed in 96-well plates. Negative-control sam-
ples, consisting of cells from naive mice incubated with peptide-pulsed P815 cells
or splenocytes from immunized mice incubated with P815 cells not pulsed with
peptide, consistently showed0.2% of CD8 T cells expressing IFN- or TNF-
(data not shown).
Statistical analysis. For protective efficacy, proportions of infected versus
noninfected animals in control and experimental groups were compared by using
the chi-square or Fisher exact (two-tailed) test as appropriate (SPSS for win-
dows, version 8.0) and are reported with 95% confidence intervals. To compare
relative immunogenicity of the vaccines, means were compared by using the
independent sample t test (SPSS for windows, version 8.0).
RESULTS
Duration of protection. To assess the duration of protection
induced by the high-dose (DG-V) and low-dose (dg-V) regi-
mens, groups of mice were immunized with either the DG-V or
the dg-V regimen as described in Materials and Methods, and
samples of 10 mice from each group were challenged with 50
infectious P. yoelii sporozoites at various intervals after immu-
nization. Figure 1 shows the proportion of protected mice at
increasing times after immunization. For both immunization
regimens, between 70 and 100% protection (mean, 87%) was
obtained up to 20 weeks postboost. There was no significant
difference between any of the time points up to 20 weeks for
either immunization regimen. Protection was decreased to 30
to 40% at 28 weeks postboost and was significant compared
FIG. 1. Duration of protection. Mice were immunized and chal-
lenged as described in Materials and Methods. Shown is the percent-
age of sterile protection observed in groups of 10 mice challenged at
the indicated times after vaccination with the DG-V (high-dose DNA)
(F) or dg-V (low-dose DNA) (E) regimen. Nonimmunized controls
() are also shown. Error bars represent 95% confidence intervals
around the proportions of protected mice.
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with the protection seen at 20 weeks (P  0.010, two-tailed
Fisher’s exact test). There was no significant difference be-
tween the high-dose (DG-V) and low-dose (dg-V) immuniza-
tion regimens (DG-V, 46 of 60  76.7%; dg-V, 48 of 60 
80%; P  0.50, chi-square test) during this period (weeks 2 to
28). These data are consistent with previous results at 2 weeks
postboost (DG-V, 23 of 18  82%; dg-V, 13 of 18  72%; P 
0.43, chi-square test) (14). To further evaluate the longevity of
protection, we selected a subset of DG-V mice shown to be
protected at 20 weeks and rechallenged them at 40 weeks
postboost. In this experiment, 8 out of 8 of the mice immunized
with the DG-V regimen were still protected at 40 weeks (0 of
10 controls challenged in parallel were protected). Overall, the
protection induced by the DG-V and dg-V regimens was main-
tained at a high level for 20 weeks and decreased between 20
and 28 weeks postboost. All mice protected at 20 weeks were
protected at 40 weeks, indicating either persistence of protec-
tion or boosting of protective immunity by the 20-week chal-
lenge.
Protection against high-dose challenge. BALB/c mice im-
munized with irradiated sporozoites are protected from chal-
lenges of 5  103 (18) to 5  105 (unpublished data) P. yoelii
sporozoites; in contrast, immunization with plasmid DNA
alone provides only partial protection against inocula of 50 to
100 sporozoites (6, 12). Therefore, we next evaluated the ca-
pacity of the DG-V and dg-V regimens to protect against a
higher dose challenge. Accordingly, at the time of the post-20-
week challenge, we randomized mice that were protected in
the 2-, 4-, 8-, or 12-week challenges into two groups and re-
challenged them with either 50 or 250 sporozoites. Protection
against challenge with 250 sporozoites was significant for both
high-dose (8 of 13 versus 0 of 10; P  0.003, two-tailed Fisher
exact test) and low-dose (5 of 14 versus 0 of 10; P  0.05,
two-tailed Fisher exact test) regimens compared with controls.
Moreover, there was essentially no difference in the capacity of
the high-dose-induced protection to withstand challenge with
either 250 or 50 sporozoites (8 of 13 [62%] versus 18 of 25
[72%]; P  0.714, two-tailed Fisher exact test). However, the
protection induced by the low-dose regimen was not as robust,
and there was a trend for reduced protection against challenge
with 250 versus 50 sporozoites (5 of 14 [36%] versus 15 of 23
[65%]; P  0.080, chi-square test).
Immune responses of immunized mice at 2 or 28 weeks after
immunization. The protection against sporozoite challenge
conferred by either irradiated sporozoites or plasmid DNA is
dependent on CD8 T cells and IFN- (4, 6, 10, 20). Recent
studies suggest that the protection induced by DNA priming
and poxvirus boosting is also dependent on CD8 T cells and
IFN- (14); in these studies the best correlates of protection
were ex vivo CTL activity and IFN- activity specific for the
CD8-T-cell epitope PyCSP(280-288) (SYVPSAEQI). We
therefore characterized T cells from immunized mice in three
assays, a standard restimulated CTL assay, a direct ex vivo CTL
assay, and an intracellular cytokine-staining assay for IFN- or
TNF-. Further, since a decrease in vaccine-induced protec-
tion was observed at 28 weeks postvaccination compared with
that at 2 weeks postvaccination, we evaluated T-cell responses
and surface phenotype at 2 and 28 weeks postvaccination. The
immunization schedule was staggered so that samples from all
groups of mice were evaluated at the same time to eliminate
any potential experiment-to-experiment variation. To confirm
the initial results of the ex vivo CTL and intracellular cytokine
staining assays, which were based on splenocytes derived from
small numbers of mice, we immunized additional groups of 20
mice with the DG-V and dg-V regimens and repeated the
assays on splenocytes from 10 individual mice sacrificed at
either 2 or 30 weeks after the viral boost.
FIG. 2. CTL responses. (a) Restimulated CTL assay. Spleen cells
from 3 mice from either the high (DG-V)- or low (dg-V)-dose DNA
group obtained at 2 or 28 weeks postboost were restimulated in vitro
for 7 days with peptide PyCSP(280-295) and used as effectors in a
chromium release CTL assay with peptide PyCSP(280-288)-labeled
targets as described in Materials and Methods. The percent lysis was
determined according to the following formula: (experimental release
 medium control release)/(maximum release  medium control re-
lease)  100. The percent specific lysis was calculated by subtracting
the percent lysis of the control targets from the percent lysis of the
specific peptide. Three mice per group were assayed individually, and
data represent the means and standard deviations of percent specific
lysis at the indicated effector-to-target-cell (E:T) ratios. (b) Ex vivo
CTL assay. Freshly isolated spleen cells from 10 mice per group ob-
tained at 2 or 30 weeks postboost were assayed individually and used
as effectors as described in Materials and Methods. Data represent the
means and standard deviations of percent specific lysis at the indicated
effector-to-target-cell ratios.
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CD8 CTL responses. As in previous studies (14), high
levels of restimulated CTL specific for the immunodominant
epitope PyCSP(280-288) were detected in both high-dose and
low-dose priming regimens at 2 weeks postboost (Fig. 2a);
there was a slight but not significant decrease in the magnitude
of restimulated CTL responses at 28 weeks compared with that
at 2 weeks. There was no apparent difference in the magnitude
of response between the high- and low-dose regimens at either
time point (Fig. 2a).
Robust ex vivo CTL responses were also detected in both
DG-V- and dg-V-immunized mice at 2 weeks postboost (Fig.
2b and data not shown), as reported previously (14). However,
we were unable to detect ex vivo CTL responses in either
DG-V- or dg-V-immunized mice at 28 or 30 weeks postboost
(Fig. 2b and data not shown). Mice immunized with a single
dose of recombinant vaccinia expressing PyCSP without DNA
priming produced lower levels of CTL in both the restimulated
and ex vivo CTL assays (Fig. 2a and data not shown).
We next evaluated antigen-specific production of IFN- and
TNF- in CD8 T cells from DG-V- or dg-V-immunized mice
at either early (2 weeks) or late (28 or 30 weeks) points after
viral boosting. As shown in Table 1, samples from DG-V-
immunized mice had marginally higher frequencies of IFN--
or TNF--secreting CD8 T cells than samples from dg-V-
immunized mice in experiment 1 and significantly higher fre-
quencies of IFN--secreting CD8 T cells in experiment 2
(DG-V versus dg-V at 2 weeks, P  0.007). At the late time
points, there was a substantial decline in the fraction of CD8
cells expressing IFN-, and to a lesser extent TNF-, although
the declines reached statistical significance only in the second
experiment conducted with 10 mice per group (IFN-, DG-V,
2 versus 30 weeks, P  0.00044; IFN-, dg-V, 2 versus 30
weeks, P 0.0014; TNF-, DG-V, 2 versus 28 weeks, P 0.58;
TNF-, dg-V, 2 versus 28 weeks, P  0.27). This decline in the
percentage of antigen-responsive CD8 cells corresponded to
a decline in the absolute number of antigen-responsive cells in
the spleen since the total number of splenocytes isolated from
the spleens was reduced by 20 to 50% in the late compared to
the early time points (data not shown). The cytokine-positive
CD8 population had the surface phenotypes CD62Llo,
CD69lo, CD45RBint, and CD44hi (Fig. 3).
To further characterize the responding cell population, we
quantitated the mean fluorescence intensity (MFI) of IFN-
and TNF- responses. As shown in Table 1, the MFI for IFN-
was greater in the IFN- CD8 splenocytes taken at 28 or 30
weeks postboost than at 2 weeks for both DG-V and dg-V
regimens (DG-V, P  0.0001; dg-V, P  0.0001; experiment
2). A similar difference was observed for the TNF- MFI but
was only significant in the case of the DG-V regimen (DG-V,
P  0.045; dg-V, P  0.159). Thus, although the number of
CD8 cells expressing IFN- and TNF- was lower at 28 or 30
weeks than at 2 weeks after boosting, the amount of IFN- and
TNF- produced per responding cell, as measured by the MFI,
was higher at 28 or 30 weeks than at 2 weeks. There was no
difference between the MFI for IFN- or TNF- observed in
cells from mice immunized with the DG-V versus dg-V regi-
mens.
Persistence of antibody responses induced by DNA plus
GM-CSF priming and poxvirus boosting. Figure 4 shows the
antibody responses in mice immunized with the DG-V or dg-V
regimens at 2 or 28 weeks after the viral boost, as measured by
enzyme immunoassay (EIA) with either a recombinant PyCSP
protein or a peptide corresponding to the immunodominant
B-cell epitope (QGPGAP) or by immunofluorescence assay
(IFA) against air-dried sporozoites. As measured by all three
assays in both DG-V and dg-V groups, there was a modest,
statistically significant, three- to sevenfold reduction in titer
between weeks 2 and 28 (CSP EIA: DG-V, P  0.002; dg-V, P
 0.004; peptide EIA: DG-V, P  0.001; dg-V, P  0.03;
sporozoite IFA: DG-V, P  0.01; dg-V, P  0.02; two-tailed t
test, log-transformed titers). Overall, titers were approximately
threefold higher in mice immunized with the DG-V regimen
than in those immunized with the dg-V regimen at both 2 and
28 weeks; however, the difference was not consistently statis-
tically significant (CSP EIA: 2 weeks, P  0.05; 28 weeks, P 
0.003; peptide EIA: 2 weeks, P  0.02; 28 weeks, P  0.11;
sporozoite IFA: 2 weeks, P  0.19; 28 weeks, P  0.05; two-
tailed t test, log-transformed titers). We further asked whether
the observed antibody responses were associated with protec-
tion. We compared the geometric mean titers in all protected,
immunized mice with those in all nonprotected, immunized
mice; titers in protected mice were modestly, but significantly,
higher in the protected mice in all three assays (CSP EIA,
32,961 versus 15,624, P 0.045; peptide EIA, 1,462 versus 452,
P  0.015; sporozoite IFA, 70,797 versus 38,343, P  0.039;
two-tailed t test on log-transformed data). A similar analysis of
T-cell responses and protection at the level of individual mice
was not possible because the T-cell assays required the sacrifice
of a subset of the animals from each group prior to challenge.
TABLE 1. Intracellular cytokine staining
Expt no. Regimen(wk post-viral boost)a
Mean % IFN- CD8
cells (SD)
Mean MFI of IFN-
CD8 cells (SD)
Mean % TNF- CD8
cells (SD)
Mean MFI of TNF-
CD8 cells (SD)
1 DG-V (2) 12.6 (2.8) 147 (29) 8.0 (0.7) 52 (1)
DG-V (28) 7.3 (7.2) 276 (44) 6.3 (4.7) 69 (7)
dg-V (2) 11.9 (7.1) 143 (12) 7.6 (4.2) 55 (6)
dg-V (28) 4.4 (0.4) 233 (20) 3.8 (0.2) 63 (6)
2 DG-V (2) 20.6 (7.4) 406 (47)
DG-V (30) 8.1 (5.2) 754 (99)
dg-V (2) 11.6 (5.7) 505 (133)
dg-V (30) 3.4 (1.8) 962 (152)
a Experiment 1, 3 mice per group; experiment 2, 10 mice per group.
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DISCUSSION
We have characterized the persistence of immunity to ma-
laria induced by a heterologous DNA priming and poxvirus
boosting regimen. In the present study, immunization with
either the DG-V or dg-V regimen induced 70 to 100% sterile
immunity from low-dose sporozoite challenge that persisted
essentially unchanged until at least 20 weeks after boosting.
Even at 28 weeks, 30 to 40% protection was seen. Further,
when a subset of mice that had been protected in the 20-week
challenge was rechallenged at 40 weeks, 8 out of 8 were pro-
tected. Thus, vaccine-induced protection persists for at least 28
weeks and, perhaps as a result of boosting by sporozoite chal-
lenge, may persist for as long as 40 weeks. Similar protection
after a delayed challenge was recently observed in the rhesus
simian-human immunodeficiency virus (SHIV) system, in
which monkeys immunized with a DNA priming and poxvirus
boosting regimen were challenged with infectious SHIV 29
weeks after the boost and were protected against AIDS and
death, although not against the primary viremia (1). In the
SHIV model, memory T cells are stimulated by a high primary
viremia and have several weeks in which to develop into acti-
vated effectors to control the infection. The P. yoelii model is in
some respects a more stringent challenge; there is only a 48-h
window between challenge and the emergence from the liver of
blood-stage parasites which do not express the vaccine target
FIG. 3. Phenotype of IFN--producing cells. Spleen cells from 3 mice per group obtained at 2 or 28 weeks postboost were cultured with
PyCSP(280-288) peptide-pulsed P815 cells for 16 h, stained with antibodies to CD8, C62L, CD45RB, CD69, and CD44, and stained intracellularly
with antibodies to IFN-. The phenotypes of IFN--producing cells on gated CD8 T cells were determined individually for each of the 3 mice
per group. Representative data from one mouse are shown. PE, phycoerythrin; FITC, fluorescein isothiocyanate.
FIG. 4. Antibody responses. Shown are titers for EIA with recom-
binant PyCSP or synthetic peptide (QGPGAP)4 or IFA against air-
dried P. yoelii sporozoites as described in Materials and Methods. For
the EIAs, results are reported as 0.5 optical density units (the recip-
rocal of the serum dilution at which the mean optical density reading
is 0.5); for IFA, results are reported as the endpoint of the serum
dilution at which immunofluorescence could be detected. Geometric
mean titers and standard deviations from groups of 10 mice are shown.
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antigen, PyCSP, and which are not affected by pre-erythrocytic
stage immune responses. Thus, preexisting memory T cells
have less than 2 days to become activated effectors and elim-
inate the liver-stage infection. It is quite remarkable, then, that
30 to 40% of mice were protected at a time when they did not
have detectable effectors in the spleen, as judged by the lack of
ex vivo CTL activity. It was therefore of considerable interest
to characterize the memory T-cell population present 28 weeks
after immunization.
There is clear evidence that protection against challenge
with P. yoelii sporozoites in BALB/c mice induced by immuni-
zation with either irradiated sporozoites or DNA vaccine plas-
mids is dependent on CD8 T cells and IFN- (5, 6, 12), and
there is suggestive evidence that the same is true for the DG-V
and dg-V regimens described here (14). In a previous study,
the best in vitro correlates of protection were the ex vivo CTL
assay used in the present study and antigen-specific IFN-
responses measured by ELISPOT (14). We therefore charac-
terized the CD8-T-cell population responsive to the predom-
inant Kd-restricted epitope from PyCSP, SYVPSAEQI, at
early (2 weeks) or late (28 or 30 weeks) times following im-
munization. Two weeks after immunization, 12 to 20% of
CD8 splenocytes produced IFN- in response to incubation
with SYVPSAEQI; by 28 weeks, this percentage dropped to 3
to 8%. In the absence of major histocompatibility complex
class I tetramer-SYVPSAEQI reagents it is impossible to de-
termine whether the reduction in antigen-responsive CD8 T
cells is due to their elimination or to their having become
unresponsive. It is also possible that they emigrated from the
spleen. There are important qualitative differences between
the 2-week (effector) and 28- to 30-week (memory) antigen-
responsive CD8-T-cell populations. Both populations ex-
pressed an effector-memory surface phenotype, CD62Llo,
CD69lo, CD45RBint, and CD44hi. Although the 2-week popu-
lation did not express the transient activation marker, CD69, it
can be identified as an effector population based on its ex vivo
CTL activity. The lack of CD69 expression in CD8 effectors
has also been described in mice responding to infection with
lymphocytic choriomeningitis virus (8). The memory popula-
tion lacked detectable ex vivo CTL activity (Fig. 2b), although
it did not significantly differ from the effector population in its
activity in a restimulated CTL assay (Fig. 2a). Interestingly,
although the percentage of antigen-responsive CD8 cells de-
clined by weeks 28 to 30, the amount of IFN- produced by
individual responsive cells increased significantly, as judged by
the increase in MFI for IFN- (Fig. 3b). The ability of the
memory CD8 cells to produce large amounts of IFN- in
response to antigen and their inability to carry out cytolysis in
a short-term ex vivo CTL assay is consistent with previous
observations of different kinetics for cytokine secretion and
cytolysis in memory CD8 cells (2), which may reflect the
greater time required for synthesis and assembly of the com-
ponents for cytolytic granules than for cytokine expression (7).
Finally, as has been described for memory cells induced by
lymphocytic choriomeningitis virus infection (15), the memory
CD8 antigen-responsive cells expressed more surface CD8
than the effector cells (data not shown).
Strong antibody responses were induced by the heterologous
immunization (Fig. 4) and declined only moderately between 2
and 28 weeks after immunization. Interestingly, there was a
significant correlation between antibody titer and protection at
the level of individual mice. In a previous study of the DG-V
regimen, Sedegah et al. found a correlation between protection
and the levels of anti-PyCSP or sporozoite antibodies induced
by a variety of DNA-based vaccination regimens (14). T-cell
responses were well correlated with the antibody titers, and the
best correlations with protection were seen with ex vivo CTL
activity and IFN- ELISPOT activity. It seems likely that in the
present study, also, the antibody titers are a surrogate for other
cellular immune responses.
The differences between the high- and low-dose priming
immunization regimens, DG-V and dg-V, were relatively mi-
nor. Antibody and IFN- responses were two- to threefold
lower with the dg-V regimen. Protection against a 50-sporozo-
ite challenge was similar. The protection induced by DG-V
appeared somewhat more robust, as it provided greater pro-
tection against a second challenge with 250 sporozoites than
did dg-V.
Overall, our data establish that heterologous vaccination by
priming with plasmid DNA coadministered with GM-CSF fol-
lowed by boosting with recombinant poxvirus induced substan-
tial protection that persisted undiminished for 20 weeks and
remained significant for at least 28 and perhaps up to 40 weeks.
The antigen-specific CD8 memory T cells responsible for this
protection lacked measurable ex vivo CTL activity but did
produce greater amounts of IFN- per cell than the effector
cells present 2 weeks after vaccination. A detailed understand-
ing of the development of immunity will depend on additional
characterization of the effector and memory CD8 popula-
tions throughout the course of immunization and challenge
and, at best, will lead to more effective strategies for inducing
protective, long-term CD8-T-cell-mediated immunity to ma-
laria and other infectious diseases.
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